A syngeneic murine KRAS G12C-driven lung cancer model used to study KRAS-targeted therapies, tumour-immune interactions, and immune checkpoint inhibition. Save 30% on this cell line this autumn. Use code ACA26CELL at checkout.
| Inventor | Institute |
|---|---|
| Julian Downward, Pablo Romero-Clavijo, Miriam Molina-Arcas | The Francis-Crick Institute |
| SKU: | 161804 |
|---|---|
| Product description: | Mouse models of mutant KRAS-driven lung cancer with an elevated tumour mutational burden by expressing the human DNA cytosine deaminase, APOBEC3B, to mimic the mutational signature seen in human lung cancer. The ability of KRAS/KRASG12 inhibitors to cause regression of KRASG12C expressing tumours was markedly potentiated by the adaptive immune system. |
| Alternate name: | KPARG12C |
| CRISPR: | No |
| Production details: | A derivative from the KPAR cells, where the mutation Asp in position 12 from KRAS (G12D) was mutated to Cys (G12C) using prime editing. |
| Model description: | A derivative from the KPAR cells, where the mutation Asp in position 12 from KRAS (G12D) was mutated to Cys (G12C) using prime editing. |
| Products or characteristics of interest: | |
| Related tools: |
| Cat. #: | 161804 |
|---|---|
| Cancer types: | Lung cancer |
| Research Fields: | Cancer |
| Organism: | Mouse |
| Tissue: | Lung |
| Model: | Mutant |
| Growth properties: | Adherent |
| Primary citation: | Boumelha et al. 2022. Cancer Research. 82(19):3435-3448. PMID: 35930804. |
| Initial handling information: | |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | DMEM, supplemented with 10% FCS, 4 mM l-glutamine, penicillin (100 U/ml), and streptomycin (100 mg/ml). |
| Subculture routine: | Split 1:12 – 1:15 twice a week. |
| Temperature: | 37°C |
| Atmosphere: | 5% CO2 |
| Storage medium: | |
| Recommended controls: | |
| Biosafety level: | 2 |
| References: |
Ng et al. 2023. Nature. 616: 563–573. PMID: 37046094 Boumelha et al. 2022. Cancer Research. 82(19):3435-3448. PMID: 35930804 Mugarza et al. 2022. Sci Adv. 8(29). PMID: 35857848 Molina-Arcas et al. 2019. Sci Transl Med. 11(510). PMID: 31534020 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.